Sam Brusco, Associate Editor04.25.22
Fresenius Medical Care North America (FMCNA) has earned U.S. Food and Drug Administration (FDA) 510(k) clearance for its VersiPD Cycler system, a next-gen, portable, automated peritoneal dialysis (APD) system.
VersiPD simple, quiet, portable, and advanced, and aims to make home dialysis a more feasible option.
"The clearance of VersiPD is another important step in our effort to make home therapies easier for patients and more efficient for clinicians," Joe Turk, president of FMCNA's Renal Therapies Group told the press. "We have listened closely to what patients and clinicians want in a home dialysis experience and have brought those ideas into the heart of this innovative system."
VersiPD’s almost silent operation, fewer disruptive alarms, and night mode helps dialysis patients sleep more restfully. It has more personalized prescription programs, a large touchscreen, and embedded videos with audio guidance to assist through setup and treatment. A cycle batter and custom care help mobility around the home.
The Kinexus therapy management platform supports VersiPD through a connected health system that features remote therapy monitoring and programming.
"We believe that our new VersiPD will empower more patients to reclaim their freedom and independence, while further enabling care teams to better support patients and intervene more quickly when necessary," said Dr. Mike Anger, chief medical officer for FMCNA's Renal Therapies Group. "We know most patients can be successful dialyzing at home with the right technology and support, and this new cycler is an important milestone in our journey to truly transform dialysis care."
The company expects a limited VersiPD rollout this year, and more widespread availability in 2023 and beyond.
VersiPD simple, quiet, portable, and advanced, and aims to make home dialysis a more feasible option.
"The clearance of VersiPD is another important step in our effort to make home therapies easier for patients and more efficient for clinicians," Joe Turk, president of FMCNA's Renal Therapies Group told the press. "We have listened closely to what patients and clinicians want in a home dialysis experience and have brought those ideas into the heart of this innovative system."
VersiPD’s almost silent operation, fewer disruptive alarms, and night mode helps dialysis patients sleep more restfully. It has more personalized prescription programs, a large touchscreen, and embedded videos with audio guidance to assist through setup and treatment. A cycle batter and custom care help mobility around the home.
The Kinexus therapy management platform supports VersiPD through a connected health system that features remote therapy monitoring and programming.
"We believe that our new VersiPD will empower more patients to reclaim their freedom and independence, while further enabling care teams to better support patients and intervene more quickly when necessary," said Dr. Mike Anger, chief medical officer for FMCNA's Renal Therapies Group. "We know most patients can be successful dialyzing at home with the right technology and support, and this new cycler is an important milestone in our journey to truly transform dialysis care."
The company expects a limited VersiPD rollout this year, and more widespread availability in 2023 and beyond.